TSTeijo I. Saari

Teijo I. Saari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teijo I. Saari has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Janne T. Backman

    Department of Clinical Pharmacology University of Helsinki Helsinki Finland

    1 shared publication
  • Jouko Laitila

    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, 00014, Helsinki, Finland

    1 shared publication
  • Kari Laine

    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, 20100, Turku, Finland

    1 shared publication
  • Klaus T. Olkkola

    Department of Anaesthesiology and Intensive Care Medicine, University of Helsinki, Helsinki, Finland

    1 shared publication
  • Kristiina Kuusniemi

    Department of Anaesthesiology and Intensive Care, University of Turku, P.O. Box 52, Kiinamyllynkatu 4-8, FI-20521, Turku, Finland

    1 shared publication
  • Mari Fihlman

    Department of Anaesthesiology and Intensive Care, University of Turku, P.O. Box 52, Kiinamyllynkatu 4-8, FI-20521, Turku, Finland

    1 shared publication

Latest Publications

  • Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction

    by Mari Fihlman, Tuija Hemmilä, Nora M. Hagelberg, Kristiina Kuusniemi, Janne T. Backman, Jouko Laitila, Kari Laine, Pertti J. Neuvonen, Klaus T. Olkkola, Teijo I. Saari

    Purpose This study aimed to determine possible effects of voriconazole and posaconazole on the pharmacokinetics and pharmacological effects of sublingual buprenorphine. Methods We used a randomized, placebo-controlled crossover study design with 12 healthy male volunteers. Subjects were given a dose of 0.4 mg (0.6 mg during placebo phase) sublingual buprenorphine after a 5-day oral pretreatment with either (i) placebo, (ii) voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter or (iii) posaconazole 400 mg twice daily. Plasma and urine concentrations of buprenorphine and its primary active metabolite norbuprenorphine were monitored over 18 h and pharmacological effects were measured. Results Compared to placebo, voriconazole increased the mean area under the plasma concentration-time curve (AUC0–∞) of buprenorphine 1.80-fold (90 % confidence interval 1.45–2.24; P < 0.001), its peak concentration (Cmax) 1.37-fold (P < 0.013) and half-life (t ½ ) 1.37-fold (P < 0.001). Posaconazole increased the AUC00-∞ of buprenorphine 1.25-fold (P < 0.001). Most of the plasma norbuprenorphine concentrations were below the limit of quantification (0.05 ng/ml). Voriconazole, unlike posaconazole, increased the urinary excretion of norbuprenorphine 1.58-fold (90 % confidence interval 1.18–2.12; P < 0.001) but there was no quantifiable parent buprenorphine in urine. Plasma buprenorphine concentrations correlated with the pharmacological effects, but the effects did not differ significantly between the phases. Conclusions Voriconazole, and to a minor extent posaconazole, increase plasma exposure to sublingual buprenorphine, probably via inhibition of cytochrome P450 3 A and/or P-glycoprotein. Care should be exercised in the combined use of buprenorphine with triazole antimycotics, particularly with voriconazole, because their interaction can be of clinical importance.